Advertisement

Advertisement

AACR Virtual Annual Meeting 2020 II

colorectal cancer

Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?

Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by genetic predisposition but m...

issues in oncology

Antoni Ribas, MD, PhD, on Racism and Racial Inequities in Cancer Research

Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes a special panel discussion on ways to eliminate cancer health disparities among rac...

issues in oncology
leukemia

Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border

Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic malignancies residing at th...

issues in oncology

Stacey A. Fedewa, PhD, on Cancers in Younger Populations: Current Trends

Stacey A. Fedewa, PhD, of the American Cancer Society, discusses the increasing incidence rates of colorectal, breast, kidney, thyroid, uterine corpus, and cervical disease in younger patients. Data s...

issues in oncology

Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?

Adam C. Palmer, PhD, of the University of North Carolina at Chapel Hill, discusses combining immune checkpoint inhibitors with other cancer therapies to provide patients with more chances of a respons...

lung cancer
immunotherapy

Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting

Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and ...

Advertisement

Advertisement



Advertisement